Susan Cleator
Imperial College Healthcare NHS Trust(GB)Charing Cross Hospital(GB)Imperial College London(GB)
Publications by Year
Research Areas
Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Cancer Genomics and Diagnostics, Advanced Radiotherapy Techniques, Breast Implant and Reconstruction
Most-Cited Works
- → Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial(2020)1,032 cited
- → Triple-negative breast cancer: therapeutic options(2007)881 cited
- → Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence(2019)487 cited
- → 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial(2019)278 cited
- → Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial(2020)235 cited
- → A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab